LV10717B - Triazolopyrimidine derivatives, method for preparation thereof, pharmaceutical compositions containing them, methods for preparing these compositions - Google Patents
Triazolopyrimidine derivatives, method for preparation thereof, pharmaceutical compositions containing them, methods for preparing these compositions Download PDFInfo
- Publication number
- LV10717B LV10717B LVP-94-60A LV940060A LV10717B LV 10717 B LV10717 B LV 10717B LV 940060 A LV940060 A LV 940060A LV 10717 B LV10717 B LV 10717B
- Authority
- LV
- Latvia
- Prior art keywords
- methyl
- formula
- propyl
- triazolo
- biphenylyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
- LV 10717 Izgudrojuma formulaFormula (I) kurā: R, ir C^-alkilgrupa vai C3.7-cikloalkilgrupa; R2 ir ūdeņraža atoms, C^-alkilgrupa, C^-lialogēnalkilgrupa, grupa -NR4R4, grupa -NHNH2i grupa -(CH2)mOR4 vai grupa -(CH2)mSR4; R4 un R4\ kas var būt vienādi vai dažādi, ir ūdeņraža atoms vai C^-alkiigrupa; m ir vesels skaitlis no 0 līdz 5; struktūra -X^Y- vai -Y=^X- ir viena no šīm divvērtīgajām grupām: R· O R* S OR" SR" NHR" I II I II | I I —N-C— . —N-C— . — N=C— . —N=C— , —N=C— . R" SOjNR’R’ I I 2 —N=C— . — N=C — 1 kur R’ un R”, kas var būt vienādi vai dažādi, ir: ūdeņraža atoms, C^-alkilgrupa, C^-halogēnalkilgrupa, grupas <(CH2)nCOORs, -(CH2)n-OR5, -(CH2)n-0-C0-R5 vai -(CH2)n-SR5, kur n ir vesels skaitlis no 1 līdz 5; r5 ir ūdeņraža atoms vai C^-alkilgrupa, fenilgrupa, piridilgrupa, tienilgrupa vai furilgrupa; r3 jr N02 vai NH2 grupa vai arī viena no šīm grupām:kā arī to tautomērās formas un sālis, sevišķi farmaceitiski pieņemamās sālis.
- 2. Triazolopirimidīna atvasinājumi pēc 1. punkta ar kopējo formulu (I), kurā: Rļ ir C^-alkilgrupa vai C3.7-cikloalkilgrupa; R2 ir ūdeņraža atoms, C^-alkilgrupa, grupa -NHNH2, grupa '(CH2)mOR4 vai grupa -(CH2)mSR4; R4 ir ūdeņraža atoms vai C,.6-alkilgrupa; m ir vesels skaitlis no 0 līdz 2; struktūra -X=^Y- vai -Y—X- ir viena no šīm divvērtīgajām grupām: R10° 110 II o r8 fl II I8 r -C-N— ; —C=N- Ml N-C— : —N=C kur: Re ir aizvietotājs no grupas: ūdeņraža atoms, -(CH2)nOH, -(CH2)nCOOH, -R12 vai -(CH2)nCOOR12; 2 LV 10717 R12 ir C^-alkilgrupa; n ir vesels skaitlis 1 vai 2; Rn ir aizvietotājs no grupas: ūdeņraža atoms, C^-alkilgrupa, C^-halogēnalkilgrupa, fenilgrupa, piridinilgrupa, grupas: -0(CH2)n0H, -OR12f -0(CH2)n0C0R12, -SH, -S(CH2)nCOOR12, -S(CH2)nOCOR12, -NH(CH2)nCOOR12, -NR13R14, -S02NR13R14l '(CH2)nOH, -(CH2)n-OR12, -COOH, -COOR12, -(CH2)nCOOH vai -(CH2)nCOOR12; kur n un R12 nozīmes ir jau minētās, R13 un R14, kas var būt vienādi vai dažādi, ir ūdeņraža atoms vai C1.6-alkilgrupa; R3 ir viena no šīm grupām:
- 3. Atvasinājumi pēc 1. vai 2. punkta, kur R, ir aizvietotājs no grupas: etilgrupa, n-propilgrupa, n-butilgrupa.
- 4. Atvasinājumi pēc jebkura iepriekšējā punkta, kur R2 ir aizvietotājs no grupas: metilgrupa, etilgrupa, metoksimetilgrupa.
- 5. Atvasinājumi pēc jebkura iepriekšējā punkta, kur struktūra -X=^- ir viena no šīm divvērtīgajām grupām:O II —C-NH O II -NH-C — S II —C-NH CH3 I —N=C— NH- NH-CH, I - l -N=C— — N=C— COOC2Hs —N=C— ou CH2COOC2H5 —N=c— 3
- 6. Atvasinājumi pēc jebkura iepriekšējā punkta, kur R3 ir 2-(5-tetrazolil)fenilgrupa.
- 7. Atvasinājums pēc 1. vai 2. punkta, proti, 7-(n-propil)-5-metil-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]- pirimidin-2(3H)ons.
- 8. Atvasinājumi pēc 1. vai 2. punkta, proti, savienojumi no grupas: 7-(n-propil)-5-metil-8-{[2'-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[4,3-c]- pirimidin-2(3H)ons; 7-(n-propil)-5-metil-3-merkapto-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4- triazolo[4,3-c]pirimidins; 7-(n-propil)-2I5-dimetil-8-{[2'-(5-tetrazolil)-4-difenilil]metil}-1,2I4-triazolo[1,5-cJ- pirimidins; 7-{n-propil)-5-metil-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]- pirimidīns; 7-(n-propil)-5-metil-2-amino-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-cl-pirimidīns; 7-(n-propil)-5-metil-2-metilamino-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]-pirimidīns; 7-(n-propil)-5-metil-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]-pirimidīna 2-karbonskābes etilesteris; 7-(n-propil)-5-metil-8-{[2,-(5-tetrazolil)-4-difeniiil]metil}-1,2,4-triazolo[1,5-c]-pirimidin'2-iletiķskābes etilesteris; 7-etil-2,5-dimetil-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]- pirimidīns; 7-(n-butil)-5-metil-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]- pirimidin-2(3H)ons; 7-(n-propil)-5-etil-8-{[2,-(5-tetrazolil)-4-difenilil]metil}-1,2,4-triazolo[1,5-c]-pirimidin-2(3H)ons; 7-(n-propil)-5-metoksimetil-8-{[2’-(5-tetrazolil)-4-difenilil]metil}-1,2,4' triazolo[1,5-c]-pirimidin-2(3H)ons. 4 LV 10717
- 9. Paņēmiens savienojumu ar kopējo formulu (I) pēc jebkura iepriekšējā punkta iegūšanai, kas atšķiras ar to, ka tas ietver starpprodukta ar formulu (X) vai (X”) pagatavošanu:kur Rļ un R2 nozīmes atbilst 1. punktā minētajām, bet V ir viena no šīm grupām:S R7 ir zemākā alkilgrupa vai benzilgrupa; U ir skābekļa vai sēra atoms vai grupa N-R”, kur R” nozīmes atbilst 1. punktā minētajām, ciklizējot savienojumu ar formulu (IX):5 kur Rļ, R2 un V nozīmes ir jau minētās, pie kam minētā ciklizācija tiek veikta, apstrādājot savienojumu (IX): ar karbonildiimidazolu, vārot tetrahidrofurānā; ar urīnvielu, karsējot bez šķīdinātāja, vai šķīdinātājā, piemēram, N-metilpirolidonā; ar kālija ksantogenātu, vārot spirtā, piemēram, metoksietanolā; ar sēroglekli spirta šķīdumā neobligātā amīna, piemēram, trietilamīna, klātienē; ar izocianātu, kam seko apstrāde ar POCI3; ar izotiocianātu, kam seko metilēšana par -SCH3 ar metiljodīdu un pēc tam termiska ciklizācija; ar ortoesteri, karsējot; vai ari ar skābes hlorīdu, kam seko ciklizācija POCI3 iedarbībā.
- 10. Paņēmiens pēc 9. punkta, kas atšķiras ar to, ka tas ietver starpprodukta ar formulu (XI) vai (XI”) pagatavošanu:V kur Rļ, R2, V, U un R" nozīmes ir jau minētās, izomerizējot minētos savienojumus ar formulu (XI) vai (XI”) bāziskā ūdens vai ūdens/spirta maisījuma vidē pie temperatūras starp 20 un 100 °C, vai ari izomerizāciju veicot skābā vidē, sildot etiķskābē neobligātā nātrija vai kālija acetāta klātienē, vai arī sildot dihlorbenzolā skudrskābes klātienē.
- 11. Paņēmiens savienojumu ar formulu (I), kuros R3 ir grupa:6 LV 10717 iegūšanai, kas atšķiras ar to, ka savienojumu ar formulu:kurā Rļ , R2, X un Y nozīmes ir jau minētās, apstrādā, piemēram, ar nātrija azīdu, dimetilformamīdā amonija sāls, piemēram, amonija hlorīda, klātienē, pie temperatūras starp 100 un 150 °C, vai ari sildot toluolā vai ksilolā ar trimetilalvas azīdu, kam seko apstrāde ar gāzveida hlorūdeņradi tetrahidrofurānā.
- 12. Farmaceitiskā kompozīcija, kas atšķiras ar to, ka tā satur farmaceitiski efektīvu daudzumu vismaz viena savienojuma ar formulu (I) pēc jebkura punkta no 1. līdz 8., vai kādas minētā savienojuma farmaceitiski pieņemamās sāls, kas neobligāti iestrādāta farmaceitiski pieņemamā atšķaidītājā, vidē vai nesējā.
- 13. Farmaceitiskā kompozīcija ar angiotenzīna II receptoru antagonista īpašībām, kas dod iespēju sekmīgi ārstēt sirds-asinsvadu slimības, sevišķi hipertenziju, sirds nepietiekamību vai artēriju sieniņu saslimšanas, kas atšķiras ar to, ka tā satur farmaceitiski efektīvu daudzumu vismaz viena savienojuma ar formulu (I) pēc jebkura punkta no 1. līdz 8., vai kādas minētā savienojuma farmaceitiski pieņemamās sāls, kas neobligāti iestrādāta farmaceitiski pieņemamā atšķaidītājā, vidē vai nesējā.
- 14. Paņēmiens farmaceitiskās kompozīcijas pagatavošanai, kas atšķiras ar to, ka farmaceitiski efektīvu daudzumu vismaz viena savienojuma ar formulu (I) pēc jebkura punkta no 1. līdz 8., vai kādas minētā savienojuma farmaceitiski pieņemamās sāls, iestrādā farmaceitiski pieņemamā atšķaidītājā, vidē vai nesējā. 7
- 15. Paņēmiens pēc 14. punkta, kas atšķiras ar to, ka farmaceitisko kompozīciju izgatavo cietu želatīna kapsulu vai tablešu formā, kuras satur no 1 līdz 400 mg aktīvās vielas, vai arī kā injicējamu formu, kura satur no 0,01 līdz 50 mg aktīvās vielas. 8
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9108486A FR2678618B1 (fr) | 1991-07-05 | 1991-07-05 | Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
Publications (2)
Publication Number | Publication Date |
---|---|
LV10717A LV10717A (lv) | 1995-06-20 |
LV10717B true LV10717B (en) | 1995-12-20 |
Family
ID=9414783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-94-60A LV10717B (en) | 1991-07-05 | 1994-03-29 | Triazolopyrimidine derivatives, method for preparation thereof, pharmaceutical compositions containing them, methods for preparing these compositions |
Country Status (23)
Country | Link |
---|---|
US (1) | US5217973A (lv) |
EP (1) | EP0521768B1 (lv) |
JP (1) | JP3140566B2 (lv) |
KR (1) | KR100243628B1 (lv) |
AT (1) | ATE101153T1 (lv) |
AU (1) | AU655288B2 (lv) |
CA (1) | CA2072233C (lv) |
CZ (1) | CZ284757B6 (lv) |
DE (1) | DE69200045T2 (lv) |
DK (1) | DK0521768T3 (lv) |
EE (1) | EE03003B1 (lv) |
ES (1) | ES2063570T3 (lv) |
FR (1) | FR2678618B1 (lv) |
HU (2) | HU220225B (lv) |
IE (1) | IE65635B1 (lv) |
IL (1) | IL102367A (lv) |
LV (1) | LV10717B (lv) |
MD (1) | MD523G2 (lv) |
NZ (1) | NZ243443A (lv) |
RU (1) | RU2103270C1 (lv) |
SK (1) | SK279902B6 (lv) |
TW (1) | TW221445B (lv) |
ZA (1) | ZA924954B (lv) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358950A (en) * | 1991-07-05 | 1994-10-25 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists |
US5389632A (en) * | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
US5387747A (en) * | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
FR2687677B1 (fr) * | 1992-02-24 | 1996-10-11 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
IT1263804B (it) * | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
US5358947A (en) * | 1993-09-13 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones |
ATE257156T1 (de) * | 1997-03-24 | 2004-01-15 | Kyowa Hakko Kogyo Kk | (1,2,4)triazolo(1,5-c)pyrimidin-derivate |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009158309A2 (en) * | 2008-06-25 | 2009-12-30 | Ligand Pharmaceuticals Inc. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
EP4419522A1 (en) * | 2021-10-19 | 2024-08-28 | Impact Therapeutics (Shanghai), Inc | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US269980A (en) * | 1883-01-02 | Horse power | ||
GB859287A (en) * | 1958-10-03 | 1961-01-18 | Ici Ltd | Triazolopyrimidine derivatives and their preparation |
GB897870A (en) * | 1959-06-15 | 1962-05-30 | Ici Ltd | s-triazolo[2, 3-c]pyrimidine derivatives |
GB951652A (en) * | 1960-06-28 | 1964-03-11 | Wallace Broadbent | Sulphamyl triazolopyrimidines and their preparation |
US4269980A (en) * | 1979-12-17 | 1981-05-26 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-c]pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-c]pyrimidines |
US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
US4532242A (en) * | 1983-05-02 | 1985-07-30 | Riker Laboratories, Inc. | Substituted triazolo[4,3-c]pyrimidines |
US4528288A (en) * | 1983-05-02 | 1985-07-09 | Riker Laboratories, Inc. | Substituted triazolo[1,5-c]pyrimidines |
US4562192A (en) * | 1984-02-03 | 1985-12-31 | G. D. Searle & Co. | 6-Substituted-5-phenyltetrazolo[1,5-a][1,2,4]triazole[1,5-c]pyrimidines, and pharmaceutical compositions containing them |
US4728652A (en) * | 1985-05-20 | 1988-03-01 | E. R. Squibb & Sons, Inc. | 2-substituted thio or oxy-4-aryl or heterocyclo-5-carboxy-1,4-dihydropyrimidines, composition containing them, and method of using them to reduce blood pressure |
US5010195A (en) * | 1988-05-25 | 1991-04-23 | The Dow Chemical Company | Herbicidal alkoxy-1,2,4-triazolo(1,5-c)primidine-2-sulfonamides |
US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
EP0435827A3 (en) * | 1989-12-28 | 1991-11-13 | Ciba-Geigy Ag | Diaza compounds |
JPH05505609A (ja) * | 1990-03-30 | 1993-08-19 | メルク・エンド・カムパニー・インコーポレーテツド | 置換ピリミジン、ピリミジノンおよびピリドリミジン |
US5177206A (en) * | 1991-10-08 | 1993-01-05 | Dowelanco | Process for the preparation of substituted N-(aryl)-1,2,4-triazolopyrimidine-2-sulfonamides |
-
1991
- 1991-07-05 FR FR9108486A patent/FR2678618B1/fr not_active Expired - Lifetime
- 1991-08-07 US US07/741,134 patent/US5217973A/en not_active Expired - Lifetime
-
1992
- 1992-06-24 CA CA002072233A patent/CA2072233C/en not_active Expired - Lifetime
- 1992-06-30 EP EP92401850A patent/EP0521768B1/fr not_active Expired - Lifetime
- 1992-06-30 DK DK92401850.0T patent/DK0521768T3/da active
- 1992-06-30 IL IL102367A patent/IL102367A/xx not_active IP Right Cessation
- 1992-06-30 ES ES92401850T patent/ES2063570T3/es not_active Expired - Lifetime
- 1992-06-30 DE DE69200045T patent/DE69200045T2/de not_active Expired - Lifetime
- 1992-06-30 AT AT92401850T patent/ATE101153T1/de active
- 1992-07-01 IE IE922015A patent/IE65635B1/en not_active IP Right Cessation
- 1992-07-02 SK SK2078-92A patent/SK279902B6/sk not_active IP Right Cessation
- 1992-07-02 AU AU19396/92A patent/AU655288B2/en not_active Expired
- 1992-07-02 CZ CS922078A patent/CZ284757B6/cs not_active IP Right Cessation
- 1992-07-03 RU SU5052543A patent/RU2103270C1/ru active
- 1992-07-03 HU HU9202227A patent/HU220225B/hu unknown
- 1992-07-03 NZ NZ243443A patent/NZ243443A/xx not_active IP Right Cessation
- 1992-07-03 ZA ZA924954A patent/ZA924954B/xx unknown
- 1992-07-04 KR KR1019920011916A patent/KR100243628B1/ko not_active IP Right Cessation
- 1992-07-04 TW TW081105325A patent/TW221445B/zh not_active IP Right Cessation
- 1992-07-06 JP JP04200200A patent/JP3140566B2/ja not_active Expired - Lifetime
-
1994
- 1994-03-29 LV LVP-94-60A patent/LV10717B/en unknown
- 1994-11-22 EE EE9400308A patent/EE03003B1/xx unknown
- 1994-12-30 MD MD95-0084A patent/MD523G2/ro active IP Right Grant
-
1995
- 1995-06-27 HU HU95P/P00446P patent/HU211473A9/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV10717B (en) | Triazolopyrimidine derivatives, method for preparation thereof, pharmaceutical compositions containing them, methods for preparing these compositions | |
ES2293064T3 (es) | 6-alcoxi-pirido-pirimidinas como inhibidores de la p-38 map quinasa. | |
EP2385053B1 (en) | Intermediates for the preparation of fused bicyclic mTOR inhibitors | |
AU2005299421B2 (en) | Compounds and compositions as inhibitors of Cannabinoid Receptor 1 activity | |
ES2388881T3 (es) | Azolopirimidinas como inhibidores de la actividad cannabinoide 1 | |
KR20020038963A (ko) | P38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환 | |
CA2653529A1 (en) | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) | |
HRP20030485A2 (en) | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | |
RU2601410C1 (ru) | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ | |
US20070049597A1 (en) | p38 MAP kinase inhibitors and methods for using the same | |
IE912114A1 (en) | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present | |
US5231094A (en) | Triazolopyrimidines which are angiotensin II receptor antagonists and pharmaceutical compositions in which they are present | |
Nicolai et al. | Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists | |
CA2128876C (en) | Triazolopyrimidine derivatives as angiotensin ii receptor antagonists | |
Ahmed et al. | Fusions of pyrido [4′, 3′: 4, 5] thieno [2, 3‐d] pyrimidines with N‐heterocyclic moieties | |
US5358950A (en) | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists | |
CA1051887A (en) | Triazolo (4,3-d) (1,4) benzodiazepine-3,6-diones | |
JPH069638A (ja) | ピラゾロピリミジン誘導体 | |
Twomey | Nucleophilic Cleavage of s-Triazolophthalazinone Derivatives | |
EP0000382A1 (en) | Pyrimido (4,5-c)pyridazines, compositions containing them and processes for their preparation |